"It is my heart-warmed and world-embracing Christmas hope and aspiration that all of us, the high, the low, the rich, the poor, the admired, the despised, the loved, the hated, the civilized, the savage (every man and brother of us all throughout the whole earth), may eventually be gathered together in a heaven of everlasting rest and peace and bliss, except the inventor of the telephone. "
Mark Twain ; Christmas greetings, 1890
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8134008 | Preparation of amorphous hydrous esomeprazole magnesium A hydrate of esomeprazole magnesium in the form of an amorphous solid is provided. Methods of preparation and use of, as well as formulation containing the hydrate of esomeprazole magnesium in the form of an amorphous solid are also provided. ... | 03/13/2012 |
| 8133994 | Preparation of aprepitant A process for preparing aprepitant. ... | 03/13/2012 |
| 8080668 | Thiazoles derivatives as AMPK activator The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5′-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds. ... | 12/20/2011 |
| 8080559 | 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin and its preparation and use for the treatment of cancer A 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2′-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2′-hydroxyethoxy)-20(S)-camptothecin dias... | 12/20/2011 |
| 8063214 | Polymorphic forms of tadalafil A process for preparing crystalline Form A of tadalafil (I), comprising crystallization from a solution of tadalafil in a solvent comprising a C3-C7 ester, a ketone, dimethylformamide, dimethylsulfoxide, ethanol, acetonitrile, a chlorinated hyd... | 11/22/2011 |
| 8063074 | Polymorphic forms of esomeprazole sodium Polymorphic crystalline Forms J, K, L, M, and N of esomeprazole sodium. ... | 11/22/2011 |
| 8049021 | Process for the preparation of fluorotetraene There is provided a process for preparing 21-acetyloxy-6-alpha-fluoro-pregna-1,4,9(11),16-tetraene-3,20-dione compound of Formula I, which comprises reacting 21-acetyloxy-pregna-1,3,5,9(11),16-pentaene-3-oxo acetate with a fluorinating agent. ... | 11/01/2011 |
| 8039619 | Process for preparing (2R,3S/2S,3R)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol Voriconazole is prepared by a process comprising condensing 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazole-1-yl)ethanone with 4-chloro-6-ethyl-5-fluoropyrimidine, in a ketone, ether, aliphatic hydrocarbon, or aromatic hydrocarbon solvent, to give (2R,3S/2S,3R)-3-(4-chl... | 10/18/2011 |
| 8013181 | Preparation of rivastigmine and its salts There are provided processes for making rivastigmine. In one embodiment, the process includes reacting S-(−)-[1-(3-hydroxyphenyl)ethyl]dimethylamine with N-ethyl-N-methyl carbamoyl chloride in the presence of an organic base to obtain a free base of rivastigmine. | 09/06/2011 |
| 8003820 | Process for preparing bisphosphonic acids A process for preparing a bisphosphonate compound comprises reacting a carboxylic acid with a phosphonating agent, in a cresol solvent. ... | 08/23/2011 |
| 7977478 | Polymorphic forms of vardenafil Crystalline polymorphic forms of vardenafil and vardenafil hydrochloride, and processes for preparing them. ... | 07/12/2011 |
| 7943781 | Process for preparing telmisartan A process comprising cyclizing 3-amino-4-butyramido-5-methylbenzoic acid to form 2-n-propyl-4-methyl-benzimidazole-6-carboxylic acid. ... | 05/17/2011 |
| 7939513 | Tetracycline derivatives as antibacterial agents In accordance with one aspect, the present invention provides a compound of general formula (I), its stereoisomers thereof and/or its pharmaceutically acceptable salts thereof, which have antibacterial activity; with methods of treating infectious diseases in warm b... | 05/10/2011 |
| 7935841 | Bisphospholanes for use as catalysts in asymmetric reactions The invention concerns an enantiomerically enriched compound of formula (1) or the opposite enantiomer thereof wherein each of Ar1—Ar4 represent the same or different aromatic groups of up to 20 carb... | 05/03/2011 |
| 7919633 | Process for preparation of celecoxib There is provided a process for preparation of celecoxib by reacting 4,4,4-trifluoro-1-[4-(methyl)phenyl]butane-1,3-dione with 4-sulphonamidophenylhydrazine or its salt in a solvent medium that contains an alkyl ester. There is also provided a process for the purifi... | 04/05/2011 |
| 7824919 | Method for analyzing activated polyethylene glycol compounds A chemical analysis method for the determination of RO(CH2CH2O)nH, RO(C2H4O)nA, and AO(C2H4O)nA in a mixture thereof, wherein R is an alkyl group, A is a functional gr... | 11/02/2010 |
| 7816484 | Method for making polyethylene glycol carbonates A method for preparing a polyalkylene glycol carbonate is disclosed comprising reacting a hydroxyl functional polyalkylene glycol and a reagent selected from carbonates and chloroformates in the presence of an aromatic solvent and an amine. ... | 10/19/2010 |
| 7790886 | Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof The present invention is related to crystalline forms of ziprasidone and its hydrochloride salt and an amorphous form of ziprasidone hydrochloride and the process for the preparation thereof. The crystalline forms and amorphous form of the invention are suitable for... | 09/07/2010 |
| 7777037 | Ziprasidone process A process for preparing ziprasidone having low levels of keto ziprasidone and hydroxy ziprasidone impurities. ... | 08/17/2010 |
| 7772398 | Process for making crystalline form I of clopidogrel hydrogen sulphate A process for preparation of crystalline Form I of clopidogrel hydrogen sulphate, that include separating the crystalline Form I of clopidogrel hydrogen sulphate from a solution of clopidogrel freebase in a solvent, which is 2-propanol or 2-butanol is provided. ... | 08/10/2010 |
| 7700779 | Crystalline forms of fexofenadine and its hydrochloride The present invention is related to novel polymorph of Fexofenadine and Fexofenadine hydrochloride of formula 1 and process of preparation thereof. The present invention is also directed to provide pure novel polymorphs of Fexofenadine and its hydrochloride by a sim... | 04/20/2010 |
| 7659406 | Process for preparing valsartan A process for preparing valsartan. ... | 02/09/2010 |
| 7612098 | Amorphous hydrous esomeprazole magnesium A hydrate of esomeprazole magnesium in the form of an amorphous solid is provided. Methods of preparation and use of, as well as formulation containing the hydrate of esomeprazole magnesium in the form of an amorphous solid are also provided. ... | 11/03/2009 |
| 7601733 | 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin and its preparation and use for the treatment of cancer A 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2′-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2′-hydroxyethoxy)-20(S)-camptothecin dias... | 10/13/2009 |
| 7601732 | Crystalline form of 5(S)-(2-hydroxyethoxy)-20(S)-camptothecin A crystalline form of 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diastereoisomer of 5(RS)-(2′-hydroxyethoxy)-20(S)-camptothecin is described that is characterized by having an X-ray powder diffraction pattern comprising one or more peak intensities expressed in ... | 10/13/2009 |
| 7547785 | Process for preparing topotecan A process for preparing topotecan. ... | 06/16/2009 |
| 7531673 | Preparation of amino acid amides A process for making amino acid amides, comprising reacting an amino acid, or acid salt of an amino acid, with a halogenating agent, or with a substance that reacts with carboxylic acids to form a leaving group, to form an intermediate, then reacting the intermediat... | 05/12/2009 |
| 7501515 | Polymorphic form of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-1-en-3-one The present invention relates to a novel polymorphic form of 17-β-(N-ter.butyl carbamoyl)-4-aza-5-α-androst-1-en-3-one (Finasteride) of the Formula (I) and processes for preparing the form. ... | 03/10/2009 |
| 7488729 | Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof The present invention is related to crystalline forms of ziprasidone and its hydrochloride salt and an amorphous form of ziprasidone hydrochloride and the process for the preparation thereof. The crystalline forms and amorphous form of the invention are suitable for... | 02/10/2009 |
| 7476737 | Eszopiclone process Eszopiclone is prepared by reacting zopiclone with an enatiomerically pure di-p-toluoyl tartaric acid, recovering a solid salt, and reacting a solid salt with a base. Zopiclone is prepared by reacting 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]-... | 01/13/2009 |
| 7439248 | Pharmaceutical composition and the process for its preparation The present invention provides a new stable pharmaceutical composition containing 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiadiazolidine-2,4-dione as active ingredient. ... | 10/21/2008 |
| 7414128 | Crystalline R-guanidines, Arginine or (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H -phenoxazin-10-yl)ethoxy]phenyl}propanoate The present invention relates to crystalline R-guanidines of (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparations and its use as therapeutic agents. More specifically the present invention relates to crystalline Arginine (2S)-2-Etho... | 08/19/2008 |
| 7365064 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I) their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts,... | 04/29/2008 |
| 7355077 | Process for preparing tolterodine A process for preparing tolterodine with high purity. ... | 04/08/2008 |
| 7314889 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, the... | 01/01/2008 |
| 7241895 | Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation This invention relates to novel polymorphic/pseudopolymorphic forms of 5-[4-[2[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleate having formula (I). The invention also relates to a pharmaceutical composition comprising the novel polymorphic fo... | 07/10/2007 |
| 7230129 | Process for the preparation of optically pure isomers of 2-(4-hydroxy phenoxy)-2-methyl-butyric acid methyl ester The invention provides a process for preparing R-(+)-2-(4-hydroxyphenoxy)-2-methyl-butyric acid methyl ester of the formula (I): Various embodiments and variants are provided. The invention also provides ... | 06/12/2007 |
| 7202254 | Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them The present invention relates to novel triazole compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their regioisomers, their rotamers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutic... | 04/10/2007 |
| 7189853 | Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts The present invention is related to a process for preparing montelukast involving the compound of formula (VI): wherein X═CN or CONH2. ... | 03/13/2007 |
| 7161004 | Processes to produce intermediates for rosuvastatin Intermediate compounds for preparing rosuvastatin are prepared by a process comprising oxidizing hydroxy groups to aldehyde groups, using sodium hypochlorite and 2,2,6,6-tetramethyl piperidinyl oxy free radical (TEMPO) as a catalyst. ... | 01/09/2007 |